New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 8, 2013
15:02 EDTINFIInfinity Pharmaceuticals reports preclinical data at ASH
Infinity Pharmaceuticals announced new preclinical data showing the activity of IPI-145, its oral inhibitor of phosphoinositide-3-kinase, PI3K,-delta and PI3K-gamma, in models of diffuse large B-cell lymphoma, DLBCL, and T-cell acute lymphoblastic leukemia, T-ALL, two difficult-to-treat hematologic malignancies, blood cancers, for which limited treatment options are available. Additionally, Phase 1 clinical data of IPI-145 in 14 patients with advanced aggressive non-Hodgkin lymphoma, aNHL, were reported, with early clinical activity observed in patients with DLBCL, Richter transformation and transformed follicular lymphoma. These findings were presented today at the 55th Annual Meeting of the American Society of Hematology, ASH. “The preclinical data reported today, as well as early clinical data in aggressive non-Hodgkin lymphoma, further underscore the potential of IPI-145 to treat a broad range of blood cancers,” stated Julian Adams, Ph.D., president of R&D at Infinity. “IPI-145 has already shown clinical activity in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, and we are advancing IPI-145 in late-stage development in these two indications. The preclinical data reported today are expanding our understanding of the mechanism of action of IPI-145 and the roles of PI3K-delta and PI3K-gamma, which will help inform further clinical development.”
News For INFI From The Last 14 Days
Check below for free stories on INFI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
17:25 EDTINFIPoint72 Asset lowers passive stake in Infinity Pharmaceuticals to 7.1% from 7.5%
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use